According to the National Osteoporosis Foundation, osteoporosis afflicts approximately 10 million Americans; approximately 34 million individuals have low bone mass, putting them at risk for osteoporosis. Unigene Laboratories Inc. (OTCBB: UGNE) is a biopharmaceutical company engaged in the oral and nasal administration of large-market peptide drugs.